The specialist life sciences debt investment trust is providing up to $62.5 million in financing to the commercial-stage biopharmaceutical company, supporting its growth and expansion plans.
The life sciences debt investor announces the date for its half year results release.
The company has announced a change in shareholding by a person closely associated with a director.
The healthcare investment trust has appointed a new non-executive director with extensive accounting and finance experience.
The investment firm Adage Capital Management L.P. has disclosed a change in its shareholding in BioPharma Credit PLC.
The pharmaceutical company has agreed to sell its European ORLADEYO® business for up to $264 million, allowing it to retire all remaining term debt.
The investment company has disclosed a change in a major shareholder's holding.
The prominent investment company has announced the appointment of a new Non-Executive Director to its board.
The life sciences debt investment trust has completed the acquisition of OptiNose and made a new $50 million investment in Paratek Pharmaceuticals, strengthening its financial position.
The company has announced a change in shareholding by a person closely associated with a director.